Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Irinotecan shows promise for triple-negative breast cancer

Publish date:: February 24, 2020

Key clinical point: Preclinical data suggest the novel topoisomerase I inhibitor irinotecan could be effective in patients with triple-negative breast cancer.

Major finding: Irinotecan produced responses in 37.5% of patient-derived xenograft models of triple-negative breast cancer.

Study details: A preclinical study of 40 patient-derived xenografts of triple-negative breast cancer.

Disclosures: The study was funded by the Intramural Program of the National Cancer Institute, PIC3i NCI-Curie, and Site de Recherche Intégrée sur le Cancer. One author is an inventor of two TOP1 inhibitors tested, indotecan and indimitecan. Two authors are coinventors of the method used to detect inactivation of the homologous recombination pathway, which is licensed to Myriad Genetics.

Citation:

Coussy F et al. Sci Transl Med. 2020 Feb 19. doi: 10.1126/scitranslmed.aax2625.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,